55 patents
Utility
Treatment of migraine
2 Jan 24
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant.
Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
Filed: 16 Jun 23
Utility
Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
19 Dec 23
Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes.
Jacob F. Pollock, Lauren E. Kokai, Cunqi Cui, Xiaojie Yu, Dennis E. Van Epps, Darin J. Messina
Filed: 31 Jul 19
Utility
Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
5 Dec 23
Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers.
Xiaojie Yu, Nicholas J. Manesis, Jacob Pollock
Filed: 8 Oct 19
Utility
Injection paradigm for administration of botulinum toxins
21 Nov 23
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache.
Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin, David W. Dodick
Filed: 14 Jun 21
Utility
Treatment of migraine
8 Aug 23
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant.
Joel Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
Filed: 22 Dec 21
Utility
Methods of treatment using a syringe extrusion accessory
27 Jun 23
A method of treatment may include providing a syringe having medicinal fluid therein for administering to a patient and coupling an attachment portion of an extrusion accessory having a handle and a pawl to a flange portion of the syringe.
Ethan W. Franklin, Justin J. Schwab
Filed: 12 Jul 19
Utility
Implant identification by radiographic means
16 May 23
A breast implant includes a flexible shell having an anterior face including an outer surface and an inner surface, and a marker attached to the inner surface of the anterior face of the shell.
David J. Schuessler, Alberto Flores-Pujol, Daniela Rodriguez-Estrada
Filed: 8 May 20
Utility
Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
9 Feb 21
Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided.
Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
Filed: 30 May 18
Utility
Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
2 Feb 21
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins.
Karina Heredia Guillen, Ahmet Tezel
Filed: 17 Oct 18
Utility
Androgen composition for treating an ophthalmic condition
2 Feb 21
The disclosure provides compositions for treating an ocular condition.
John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani
Filed: 28 Nov 16
Utility
Microdermabrasion treatment heads
26 Jan 21
An abrasive tip is used to exfoliate skin and tissue through abrasive materials integrated in the tip.
N. Brendon Boone, III, Basil M. Hantash, Kenneth B. Karasiuk, Steven E. Wojcik
Filed: 23 May 17
Utility
Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
26 Jan 21
The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
Richard L. Beard, John E. Donello, Veena Viswanath
Filed: 22 Jan 19
Utility
Immuno-based retargeted endopeptidase activity assays
26 Jan 21
The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
Filed: 8 Jul 19
Utility
Bioerodible matrix for tissue involvement
26 Jan 21
Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture.
Dennis E. Van Epps, Thomas E. Powell
Filed: 9 Dec 16
Utility
Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
12 Jan 21
Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.
Peter A. Simmons, Joseph G. Vehige
Filed: 23 Jan 18
Utility
Biodegradable intravitreal tyrosine kinase implants
4 Jan 21
Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time.
Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
Filed: 9 Sep 18
Utility
Suture line administration technique using botulinum toxins
28 Dec 20
The present invention utilizes patient-specific landmarks in order to treat headache pain.
Andrew M. Blumenfeld
Filed: 3 Mar 19
Utility
Extended release biodegradable ocular implants
28 Dec 20
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions.
Thierry Nivaggioli, James Jane-Guo Shiah, Qing Lin
Filed: 16 Dec 18
Utility
Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
21 Dec 20
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin.
Michael S. Singer, Murat V. Kalayoglu
Filed: 16 Nov 17
Utility
Joint fat pad formulations, and methods of use thereof
21 Dec 20
The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease.
Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
Filed: 27 Jan 16